Last reviewed 2026-04-19 · How we verify

MEDROXALOL

Phase 2 active Small molecule

MEDROXALOL is a medroxalol drug. It is currently in Phase 2 development.

Medroxalol blocks the beta-1 adrenergic receptor to decrease heart rate and blood pressure.

Medroxalol is a small molecule drug that targets the beta-1 adrenergic receptor. It is classified as a medroxalol, but its commercial status is unknown. The exact indications for medroxalol are also unclear, but it is known to have a half-life of 11.0 hours and bioavailability of 38%. As a beta-1 adrenergic receptor antagonist, medroxalol works by blocking the effects of epinephrine, leading to decreased heart rate and blood pressure. Further information on its development, approval, and generic status is not available.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEDROXALOL
Drug class	medroxalol
Target	Alpha-1A adrenergic receptor, Beta-1 adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your heart is like a racing car engine. The beta-1 adrenergic receptor is like the accelerator pedal. When it's stimulated, the engine (heart) speeds up. Medroxalol is like a brake that blocks the accelerator pedal, slowing down the engine and reducing the heart rate and blood pressure.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MEDROXALOL CI brief — competitive landscape report
MEDROXALOL updates RSS · CI watch RSS

Frequently asked questions about MEDROXALOL

What is MEDROXALOL?

MEDROXALOL is a medroxalol drug.

How does MEDROXALOL work?

Medroxalol blocks the beta-1 adrenergic receptor to decrease heart rate and blood pressure.

What drug class is MEDROXALOL in?

MEDROXALOL belongs to the medroxalol class. See all medroxalol drugs at /class/medroxalol.

What development phase is MEDROXALOL in?

MEDROXALOL is in Phase 2.

What does MEDROXALOL target?

MEDROXALOL targets Alpha-1A adrenergic receptor, Beta-1 adrenergic receptor and is a medroxalol.

Drug class: All medroxalol drugs
Target: All drugs targeting Alpha-1A adrenergic receptor, Beta-1 adrenergic receptor
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing